Citations

Clear

9383 citation(s) found for "Thomas, PS".

Reflecting on Progress in and Establishing Benchmarks for Sex and Gender Health Education
Barr, Elizabeth , Chin, Eliza Lo, Rojek, Mary K., Sleeper, Rebecca B. , Temkin, Sarah M. , Clayton, Janine A. , Kantarci, Kejal , Kling, Juliana M. , McGregor, Alyson J. , Schiebinger, Londa , Viggiano, Thomas R., Wood, Susan F. , Werbinski, Jan, Temkin, Sarah M , Clayton, Janine A , Kantarci, Kejal , Kling, Juliana M , Schiebinger, Londa , Templeton, Kimberly , Newman, Connie B. , Templeton, Kimberly

Mayo Clinic

Academic Medicine | September 23, 2023 | Volume: 99 | Issue: 1 | Pages: 16-21

10.1097/acm.0000000000005444 | PMID 37734039 Get It

Abstract Sex and gender influence every aspect of human health; thus, sex- and gender-related topics should be incorporated in all aspects of health education curricula. Sex and gender health education (SGHE) is the rigorous, intersectional, data-driven integration of sex and gender into all elements of health education. A multisectoral group of thought leaders has collaborated to advance SGHE since 2012. This cross-sector collaboration to advance SGHE has been successful on several fronts, primarily developing robust interprofessional SGHE programs, hosting a series of international SGHE summits, developing sex- and gender-specific resources, and broadening the collaboration beyond medical education. However, other deeply entrenched challenges have proven more difficult to address, including accurate and consistent sex and gender reporting in research publications, broadening institutional support for SGHE, and the development and implementation of evaluation plans for assessing learner outcomes and the downstream effects of SGHE on patient care. This commentary reflects on progress made in SGHE over the first decade of the current collaboration (2012–2022), articulates a vision for next steps to advance SGHE, and proposes 4 benchmarks to guide the next decade of SGHE: (1) integrate sex, gender, and intersectionality across health curricula; (2) develop sex- and gender-specific resources for health professionals; (3) improve sex and gender reporting in research publications; and (4) develop evaluation plans to assess learner and patient outcomes.
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Ali, Lestat R. , Lenehan, Patrick J. , Cardot‐Ruffino, Victoire , Costa, Andressa Dias , Bauer, Todd W. , Nowak, Jonathan A. , Wolpin, Brian M. , Abrams, Thomas A. , Patel, Anuj , Clancy, Thomas E. , Wang, Jiping , Mancias, Joseph D. , Stucky, Chee‐Chee , Bekaii‐Saab, Tanios , Merchant, Nipun B. , Slingluff, Craig L. , Rahma, Osama E. , Dougan, Stephanie K. , Dias Costa, Andressa , Katz, Matthew H G , Bauer, Todd W , Nowak, Jonathan A , Wolpin, Brian M , Abrams, Thomas A , Patel, Anuj , Clancy, Thomas E , Wang, Jiping , Mancias, Joseph D , Reilley, Matthew J , Stucky, Chee-Chee H , Bekaii-Saab, Tanios S , Elias, Rawad , Merchant, Nipun , Slingluff, Craig L , Rahma, Osama E , Dougan, Stephanie K , Lenehan, Patrick J , Katz, Matthew H. G. , Reilley, Matthew J. , Elias, Rawad

Mayo Clinic

Clinical Cancer Research | September 21, 2023 | Volume: 30 | Issue: 3 | Pages: 542-553

10.1158/1078-0432.ccr-23-1444 | PMID 37733830 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) trials have evaluated CTLA-4 and/or PD-(L)1 blockade in patients with advanced disease in which bulky tumor burden and limited time to develop antitumor T cells may have contributed to poor clinical efficacy. Here, we evaluated peripheral blood and tumor T cells from patients with PDAC receiving neoadjuvant chemoradiation plus anti–PD-1 (pembrolizumab) versus chemoradiation alone. We analyzed whether PD-1 blockade successfully reactivated T cells in the blood and/or tumor to determine whether lack of clinical benefit could be explained by lack of reactivated T cells versus other factors. Experimental Design: We used single-cell transcriptional profiling and TCR clonotype tracking to identify TCR clonotypes from blood that match clonotypes in the tumor. Results: PD-1 blockade increases the flux of TCR clonotypes entering cell cycle and induces an IFNγ signature like that seen in patients with other GI malignancies who respond to PD-1 blockade. However, these reactivated T cells have a robust signature of NF-κB signaling not seen in cases of PD-1 antibody response. Among paired samples between blood and tumor, several of the newly cycling clonotypes matched activated T-cell clonotypes observed in the tumor. Conclusions: Cytotoxic T cells in the blood of patients with PDAC remain sensitive to reinvigoration by PD-1 blockade, and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti–PD-1 reinvigoration and marks these T cells as non-productive contributors to antitumor immunity. See related commentary by Lander and DeNardo, p. 474
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL
Xu‐Monette, Zijun Y. , Li, Yong , Snyder, Thomas M. , Yu, Tiantian , Lu, Tingxun , Tzankov, Alexandar , Visco, Carlo , Bhagat, Govind , Qian, Wenbin , Dybkær, Karen , Chiu, April , Tam, Wayne , Zu, Youli , Hagemeister, Fredrick B., Wang, Yingjun , Ferreri, Andrés J.M. , Møller, Michael , Parsons, Benjamin M. , Fan, Xiangshan , Au, Qingyan , Zhang, Mingzhi , Shaughnessy, John D. , Xu, Bing , Young, Ken H. , Snyder, Thomas , Lu, Tingxun , Hsi, Eric D , Hagemeister, Fredrick B , Wang, Yingjun , Go, Heounjeong , Ponzoni, Maurilio , Ferreri, Andrés J M , Møller, Michael Boe , Parsons, Benjamin M , Fan, Xiangshan , van Krieken, J Han , Piris, Miguel , Winter, Jane N , Au, Qingyan , Kirsch, Ilan , Zhang, Mingzhi , Shaughnessy, John , Xu, Bing , Young, Ken H , Tzankov, Alexandar , Dybkaer, Karen , Li, Yong , Bhagat, Govind , Zu, Youli , Xu-Monette, Zijun Y , Hsi, Eric D. , Go, Heounjeong , Ponzoni, Maurilio , Krieken, J. Han van , Piris, Miguel Á. , Winter, Jane N. , Kirsch, Ilan R.

Mayo Clinic

Clinical Cancer Research | September 20, 2023 | Volume: 29 | Issue: 23 | Pages: 4808-4821

10.1158/1078-0432.ccr-23-1554 | PMID 37728879 Get It

Abstract Purpose: Tumor-infiltrating B lymphocytes (TIL-B) have demonstrated prognostic and predictive significance in solid cancers. In this study, we aimed to distinguish TIL-Bs from malignant B-cells in diffuse large B-cell lymphoma (DLBCL) and determine the clinical and biological significance. Experimental Design: A total of 269 patients with de novo DLBCL from the International DLBCL R-CHOP Consortium Program were studied. Ultra-deep sequencing of the immunoglobulin genes was performed to determine B-cell clonotypes. The frequencies and numbers of TIL-B clonotypes in individual repertoires were correlated with patient survival, gene expression profiling (GEP) data, and frequencies of DLBCL-infiltrating immune cells quantified by fluorescent multiplex IHC at single-cell resolution. Results: TIL-B abundance, evaluated by frequencies of normal B-cell clonotypes in the immunoglobulin repertoires, remarkably showed positive associations with significantly better survival of patients in our sequenced cohorts. DLBCLs with high versus low TIL-B abundance displayed distinct GEP signatures, increased pre-memory B-cell state and naïve CD4 T-cell state fractions, and higher CD4+ T-cell infiltration. TIL-B frequency, as a new biomarker in DLBCL, outperformed the germinal center (GC) B-cell–like/activated B-cell–like classification and TIL-T frequency. The identified TIL-B–high GEP signature, including genes upregulated during T-dependent B-cell activation and those highly expressed in normal GC B cells and T cells, showed significant favorable prognostic effects in several external validation cohorts. Conclusions: TIL-B frequency is a significant prognostic factor in DLBCL and plays a crucial role in antitumor immune responses. This study provides novel insights into the prognostic determinants in DLBCL and TIL-B functions with important therapeutic implications.
The Inherited KRAS -variant as a Biomarker of Cetuximab Response in NSCLC
Weidhaas, Joanne B. , Hu, Chen , Komaki, Ritsuko , Masters, Gregory A. , Blumenschein, George R. , Chang, Joe Y. , Lu, Bo , Dicker, Adam P. , Bogart, Jeffrey A. , Garces, Yolanda I. , Narayan, Samir , Robinson, Clifford G. , Kavadi, Vivek S. , Koprowski, Christopher D. , Welsh, James W. , Gore, Elizabeth , MacRae, Robert M. , Bradley, Jeffrey D. , Greenberger, Joel S , Koprowski, Christopher D , Welsh, James , MacRae, Robert M , Paulus, Rebecca , Bradley, Jeffrey , Robinson, Clifford , Dicker, Adam P , Paulus, Rebecca

Mayo Clinic

Cancer Research Communications | September 20, 2023 | Volume: 3 | Issue: 10 | Pages: 2074-2081

10.1158/2767-9764.crc-23-0084 | PMID 37728512 Get It

Abstract Purpose: RTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non–small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy, plus or minus cetuximab. Although the study was negative, based on prior evidence that patients with the KRAS-variant, an inherited germline mutation, benefit from cetuximab, we evaluated KRAS-variant patients in RTOG 0617. Experimental Design: From RTOG 0617, 328 of 496 (66%) of patients were included in this analysis. For time-to-event outcomes, stratified log-rank tests and multivariable Cox regression models were used. For binary outcomes, Cochran—Mantel–Haenzel tests and multivariable logistic regression models were used. All statistical tests were two sided, and a P value <0.05 was considered significant. Results: A total of 17.1% (56/328) of patients had the KRAS-variant, and overall survival rates were similar between KRAS-variant and non-variant patients. However, there was a time-dependent effect of cetuximab seen only in KRAS-variant patients—while the hazard of death was higher in cetuximab-treated patients within year 1 [HR = 3.37, 95% confidence interval (CI): 1.13–10.10, P = 0.030], death was lower from year 1 to 4 (HR = 0.33, 95% CI: 0.11–0.97, P = 0.043). In contrast, in non-variant patients, the addition of cetuximab significantly increased local failure (HR = 1.59, 95% CI: 1.11–2.28, P = 0.012). Conclusions/Discussion: Although an overall survival advantage was not achieved in KRAS-variant patients, there is potential impact of cetuximab for this genetic subset of patients. In contrast, cetuximab seems to harm non-variant patients. These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy. Significance: The KRAS-variant is the first functional, inherited miRNA-disrupting variant identified in cancer. Our findings support that cetuximab has a potentially beneficial impact on KRAS-variant patients treated with radiation. The work confirms prior evidence that KRAS-variant patients are a subgroup who are especially sensitive to radiation. These findings further support the potential of this class of variants to enable true treatment personalization, considering the equally important endpoints of response and toxicity.
Early antibody treatment, inflammation, and risk of post-COVID conditions
Heath, Sonya L. , Fukuta, Yuriko , Zhu, Xianming , Baksh, Sheriza , Abraham, Allison G., Habtehyimer, Feben , Shade, David , Ruff, Jessica E. , Ram, Malathi , Laeyendecker, Oliver , Fernández, Reinaldo E. , Patel, Eshan U. , Baker, Owen R. , Cachay, Edward R. , Gerber, Jonathan M. , Forthal, Donald N. , Hammitt, Laura L. , Huamán, Moisés A. , Patel, Bela , Gniadek, Thomas J. , Blair, Janis E. , Lane, Karen , McBee, Nichol , Gawad, Amy L., Das, Piyali, Bloch, Evan M. , Zhu, Xianming , Laeyendecker, Oliver , Patel, Eshan U , Forthal, Donald N , Sutcliffe, Catherine G , Klein, Sabra L , Pekosz, Andrew , Bloch, Evan M , Casadevall, Arturo , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Gebo, Kelly A , Shoham, Shmuel , Currier, Judith S. , Meisenberg, Barry R. , Levine, Adam C , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Anjan, Shweta , Kassaye, Seble , Hanley, Daniel F. , Casadevall, Arturo , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

mBio | September 19, 2023 | Volume: 14 | Issue: 5 | Pages: No page available

10.1128/mbio.00618-23 | PMID 37724870 Get It

Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14.5%) and anosmia (14.5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2.69 [1.93–3.81]), older age (AOR = 1.32 [1.17–1.50]), and elevated baseline levels of IL-6 (AOR = 1.59 [1.02–2.47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC. IMPORTANCE Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.
Episodic Cocaine Use as a Cause of Venous Thromboembolism and Acute Liver Injury
Patel, Khyati H., Thomas, Kyle C., Stacey, Stephen K , Thomas, Kyle

Mayo Clinic

American Journal of Case Reports | September 19, 2023 | Volume: 24 | Issue: No issue available | Pages: No page available

10.12659/ajcr.941360 | PMID 37872733 Get It

Outcomes of revision versus re-revision reverse total shoulder arthroplasty: A case–control-matched cohort study
O’Keefe, Daniel S. , Teurlings, Tyler , Hao, Kévin A. , Saengchote, Supreeya A. , Wright, Thomas W. , Struk, Aimee M., King, Joseph J. , S O'Keefe, Daniel , Teurlings, Tyler L , Schoch, Bradley S , King, Joseph J , Hao, Kevin A , Schoch, Bradley S. , Farmer, Kevin W.

Mayo Clinic

Shoulder & Elbow | September 19, 2023 | Volume: 16 | Issue: 5 | Pages: 543-550

10.1177/17585732231202214 | PMID 39473473 Get It

Background The increasing incidence of reverse total shoulder arthroplasties (RTSA) has led to an increase in revision surgery. We aimed to compare patients undergoing re-revision RTSA to a matched cohort undergoing first-revision RTSA. Methods A retrospective review of all revision RTSAs was performed at a single institution. Sixteen shoulders that underwent re-revision RTSA were matched 1:3 to shoulders that underwent revision RTSA with a minimum two-year follow-up. Outcome scores including the American Shoulder and Elbow Surgeons Shoulder Score (ASES), Short-Form 12 (SF-12), Shoulder Pain and Disability Index (SPADI), and Simple Shoulder Test (SST) scores, range of motion (ROM), and improvement from preoperative to postoperative outcomes after re-revision RTSA were assessed. Additionally, postoperative outcomes after re-revision RTSA were compared to patients that underwent first revision RTSA and subsequently compared to the minimal clinically important difference (MCID) values for the outcome scores and ROM measurements assessed. Results Sixteen shoulders that underwent re-revision RTSA and 78 revision RTSAs met the final inclusion criteria to be included in this study. Significant improvement from preoperative to postoperative re-revision RTSA was seen in the ASES score (p = 0.046), SPADI score (p = 0.044), SST (p = 0.008), abduction (p = 0.016), and elevation (p = 0.025), but not the SF-12 score (p = 0.396), external rotation (p = 0.449), or internal rotation (p = 0.451). Outcomes after revision RTSA were found to be superior to outcomes after re-revision RTSA for all outcome scores (ASES p = 0.029, SF-12 p = 0.018, SPADI p = 0.003) except the SST score (p = 0.080) and all ROM measures (p > 0.05 for all). Internal rotation was equivalent postoperatively between both groups. From preoperative to postoperative re-revision RTSA, the mean improvement exceeded the MCID for the SST score, abduction, forward elevation, and external rotation. When comparing postoperative revision RTSA to postoperative re-revision RTSA, the mean difference between revision and re-revision RTSA exceeded the MCID for the SPADI score and external rotation. The complication rate was 19% in shoulders undergoing first revision and 41% in shoulders undergoing re-revision RTSA. Conclusion Patients undergoing re-revision RTSA receive improvement in clinical outcomes, but do not achieve outcomes comparable to those achieved after first revision RTSA.
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
Rahman, Rifaquat , Trippa, Lorenzo , Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , Fell, Geoffrey, McCluskey, Christine , Wiley, Jennifer, Gaffey, Sarah, Welch, Mary , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Beroukhim, Rameen , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Mellinghoff, Ingo K. , Haas‐Kogan, Daphne A. , Tanguturi, Shyam , Cagney, Daniel , Aizer, Ayal A. , Doherty, Lisa, Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Geduldig, Jack , Watkinson, Fiona , Pisano, William , Ramkissoon, Shakti, Reardon, David A. , Wen, Patrick Y. , Touat, Mehdi , Welch, Mary R , Ahluwalia, Manmeet S , Colman, Howard , Nabors, Louis Burt , Chukwueke, Ugonma N , Nayak, Lakshmi , Batchelor, Tracy T , Kaley, Thomas , Lu-Emerson, Christine , Mellinghoff, Ingo K , Bi, Wenya Linda , Peruzzi, Pier Paolo , Haas-Kogan, Daphne , Aizer, Ayal , Geduldig, Jack , Pisano, William , Chiocca, E Antonio , Reardon, David A , Alexander, Brian M , Ligon, Keith L , Wen, Patrick Yung , Tanguturi, Shyam K , Arrillaga‐Romany, Isabel , Fell, Geoffrey G. , Drappatz, Jan , Galanis, Evanthia , Nabors, Burt , McFaline-Figueroa, J Ricardo , Arnaout, Omar M. , Malinowski, Seth W. , Santagata, Sandro , Meredith, David M. , Alexander, Brian M.

Mayo Clinic

Journal of Clinical Oncology | September 18, 2023 | Volume: 41 | Issue: 36 | Pages: 5524-5535

10.1200/jco.23.00493 | PMID 37722087 Get It

PURPOSE The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for phase III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human epidermal growth factor receptor 2 inhibitor], and CC-115 [a deoxyribonucleic acid–dependent protein kinase/mammalian target of rapamycin inhibitor]) were simultaneously evaluated against a common control arm. We report the results for each arm and examine the feasibility and conduct of the adaptive platform design. PATIENTS AND METHODS Patients with newly diagnosed O 6 -methylguanine–DNA methyltransferase-unmethylated glioblastoma were eligible if they had tumor genotyping to identify prespecified biomarker subpopulations of dominant glioblastoma signaling pathways (EGFR, phosphatidylinositol 3-kinase, and CDK). Initial random assignment was 1:1:1:1 between control (radiation therapy and temozolomide) and the experimental arms. Subsequent Bayesian adaptive randomization was incorporated on the basis of biomarker-specific progression-free survival (PFS) data. The primary end point was overall survival (OS), and one-sided P values are reported. The trial is registered with ClinicalTrials.gov (identifier: NCT02977780 ). RESULTS Two hundred thirty-seven patients were treated (71 control; 73 abemaciclib; 81 neratinib; 12 CC-115) in years 2017-2021. Abemaciclib and neratinib were well tolerated, but CC-115 was associated with ≥ grade 3 treatment-related toxicity in 58% of patients. PFS was significantly longer with abemaciclib (hazard ratio [HR], 0.72; 95% CI, 0.49 to 1.06; one-sided P = .046) and neratinib (HR, 0.72; 95% CI, 0.50 to 1.02; one-sided P = .033) relative to the control arm but there was no PFS benefit with CC-115 (one-sided P = .523). None of the experimental therapies demonstrated a significant OS benefit ( P > .05). CONCLUSION The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.
LONG-TERM POST-MARKETING SURVEILLANCE DATA FROM ELDERLY PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY
Mrugała, Maciej M. , Heidemann, Martina, Lukas, Rimas V. , Glas, Martin , Shi, Wenyin , IWAMOTO, FABIO MASSAITI , Palmer, Joshua D. , Suh, John H.

Mayo Clinic

Neuro-Oncology | September 16, 2023 | Volume: 25 | Issue: Supplement_3 | Pages: iii2-iii2

10.1093/neuonc/noad147.007 Get It

Abstract AIMS Glioblastoma (GBM) has a poor prognosis, which is compounded by an increase in treatment-related toxicity with age. TTFields are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability. Subgroup analysis of the phase 3 EF-14 study demonstrated TTFields therapy to be well-tolerated in patients ≥65 years with newly diagnosed (nd) GBM. We report safety data in elderly patients from a global post- marketing surveillance (PMS) analysis of patients with central nervous system (CNS) malignancies receiving TTFields. METHOD PMS data was collected from patients receiving TTFields (October 2011–March 2022) in North America, Europe, Middle East, Africa, and Japan. Adverse events (AEs) were categorized using MedDRA version 25.1. RESULTS Overall, 25,898 patients were included (diagnoses: ndGBM [68%], recurrent GBM [26%], anaplastic astrocytoma/oligodendroglioma [4%], other [2%]). Of these, 7808 patients (30%) were elderly (>65 years). 75% of elderly patients experienced ≥1 AE, with 57% related to TTFields; comparable frequencies to the overall population (73% and 56%, respectively). The most common treatment-related AE in elderly patients was skin reaction (45%; overall population: 43%). Incidence of treatment-related fall and fracture in elderly patients was 1% and <1%, respectively. Incidence of treatment-related ‘quality-of-life decreased’ was 2% (elderly and overall). No systemic toxicities were reported, regardless of age group. CONCLUSIONS These real-world data demonstrate TTFields has a tolerable safety profile in elderly patients with CNS malignancies, consistent with elderly subgroup data from EF-14, and with no new safety signals. Most AEs were localised, manageable, mild–moderate skin reactions.
Morphological characteristics of brain aneurysms among age groups
Sanchez, Sebastian , Essibayi, Muhammed Amir , Hickerson, Meredith, Ojeda, Diego J, Kasab, Sami Al , Levitt, Michael R. , Cuellar, Hugo , Brinjikji, Waleed , Spiotta, Alejandro M , Cuellar-Saenz, Hugo H , Samaniego, Edgar A , Levitt, Michael R , Essibayi, Muhammed Amir , Yoshimura, Shinichi , Jabbour, Pascal , Mascitelli, Justin R , Shaban, Amir

Mayo Clinic

Interventional Neuroradiology | September 16, 2023 | Volume: 32 | Issue: 3 | Pages: 345-351

10.1177/15910199231201520 | PMID 37715650 Get It

Background Patient's age is an important factor in determining the risk of aneurysm rupture. However, there is limited data on how aneurysm morphology differs among age groups. We studied morphological characteristics of brain aneurysms among age groups in a large cohort. Methods Aneurysms from the Stroke Thrombectomy and Aneurysm Registry (STAR) were analyzed. The following parameters were included: location, size, neck, width, height, aspect ratio, and regular versus irregular morphology. The risk of rupture presentation was estimated using logistic regression. Results A total of 1407 unruptured and 607 ruptured saccular aneurysms were included. The most common locations of ruptured aneurysms in patients younger than 70 years-old were the middle cerebral artery (MCA) and the anterior communicating artery (ACOM). The most common location of ruptured aneurysms in patients older than 70 years-old were the posterior communicating artery (PCOM) and ACOM. The size of unruptured aneurysms increased with age (p < .001). Conversely, the size of ruptured aneurysms was similar among age groups (p = .142). Unruptured and ruptured aneurysms became more irregular at presentation with older age (p < .001 and p .025, respectively). Irregular morphology and location were associated with rupture status across all age groups in multivariate regression. Conclusions Younger patients have small unruptured and ruptured aneurysms, and ruptured aneurysms are mostly located in the MCA and ACOM. Older patients have larger and more irregular unruptured aneurysms, and ruptured aneurysms are mostly located in the PCOM and ACOM. An irregular morphology increases the risk of rupture in all age groups.